Literature DB >> 27321992

Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features.

Amanda H Seipel1, Brett Delahunt2, Hemamali Samaratunga3, Lars Egevad4.   

Abstract

Ductal adenocarcinoma of the prostate (DAC) is recognised as a subtype of prostatic adenocarcinoma, but its diagnostic criteria and biology remain controversial. DAC was first thought to stem from Müllerian duct remnants, but further studies suggest a prostatic origin. DAC is composed of tall, columnar, pseudostratified epithelium with a papillary, cribriform, glandular or solid architecture. The diagnosis is based on morphology alone with papillary architecture being the most helpful diagnostic feature. The tumour is rare in a pure form and most cases are combined with acinar adenocarcinoma. The most common differential diagnoses of DAC are intraductal carcinoma of the prostate and high-grade prostatic intraepithelial neoplasia. Patients often present at an advanced clinicopathological stage. High rates of extra-prostatic extension, seminal vesicle invasion, local and regional metastases, and positive surgical margins are seen after radical prostatectomy. DAC metastasises to sites that are less commonly seen for prostate cancer such as lung, brain, testis and penis. The morphology and the unusual metastatic locations make the accurate diagnosis of metastases challenging, but a positive immunostain for prostate specific markers may be helpful. The correct identification of DAC has implications for treatment as well as outcome.
Copyright © 2016 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Prostate; ductal adenocarcinoma; pathology; prognosis; prostatectomy

Mesh:

Year:  2016        PMID: 27321992     DOI: 10.1016/j.pathol.2016.04.001

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  11 in total

1.  Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.

Authors:  Marc Gillard; Justin Lack; Andrea Pontier; Divya Gandla; David Hatcher; Adam G Sowalsky; Jose Rodriguez-Nieves; Donald Vander Griend; Gladell Paner; David VanderWeele
Journal:  Eur Urol Focus       Date:  2017-12-08

Review 2.  Histopathology of Prostate Cancer.

Authors:  Peter A Humphrey
Journal:  Cold Spring Harb Perspect Med       Date:  2017-10-03       Impact factor: 6.915

Review 3.  [Prostate and breast cancer: similarities and differences].

Authors:  Jennifer Kranz; Marco Hoffmann; Katja Krauß; Elmar Stickeler; Matthias Saar
Journal:  Urologie       Date:  2022-08-29

Review 4.  Cribriform Patterned Lesions in the Prostate Gland with Emphasis on Differential Diagnosis and Clinical Significance.

Authors:  Maria Destouni; Andreas C Lazaris; Vasiliki Tzelepi
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

Review 5.  Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management.

Authors:  Nithesh Ranasinha; Altan Omer; Yiannis Philippou; Eli Harriss; Lucy Davies; Ken Chow; Paolo M Chetta; Andrew Erickson; Timothy Rajakumar; Ian G Mills; Richard J Bryant; Freddie C Hamdy; Declan G Murphy; Massimo Loda; Christopher M Hovens; Niall M Corcoran; Clare Verrill; Alastair D Lamb
Journal:  BJUI Compass       Date:  2021-01-05

Review 6.  Optimizing the diagnosis and management of ductal prostate cancer.

Authors:  Weranja Ranasinghe; Daniel D Shapiro; Miao Zhang; Tharakeswara Bathala; Nora Navone; Timothy C Thompson; Bradley Broom; Ana Aparicio; Shi-Ming Tu; Chad Tang; John W Davis; Louis Pisters; Brian F Chapin
Journal:  Nat Rev Urol       Date:  2021-04-06       Impact factor: 14.432

7.  Perineal recurrence of prostate ductal adenocarcinoma after transperineal brachytherapy: a case report and literature review.

Authors:  Takashi Fukagai; Kidai Hirayama; Masashi Morita; Kota Nishimura; Jin Yamatoya; Tetsuo Noguchi; Yu Ogawa; Atsushi Igarashi; Madoka Morota; Masako Kato; Kazuhiko Oshinomi; Yoshio Ogawa; Toyonori Tsuzuki
Journal:  J Contemp Brachytherapy       Date:  2020-12-16

8.  Oncological outcomes of patients with ductal adenocarcinoma of the prostate receiving radical prostatectomy or radiotherapy.

Authors:  Mengzhu Liu; Kun Jin; Shi Qiu; Pengyong Xu; Mingming Zhang; Wufeng Cai; Xiaonan Zheng; Lu Yang; Qiang Wei
Journal:  Asian J Urol       Date:  2020-05-23

9.  Vasohibin-1 expression as a biomarker of aggressive nature in ductal adenocarcinoma of the prostate: a retrospective cohort study at two centres in Japan.

Authors:  Hiroaki Kobayashi; Takeo Kosaka; Shuji Mikami; Tokuhiro Kimura; Hiroshi Hongo; Michio Kosugi; Yasufumi Sato; Mototsugu Oya
Journal:  BMJ Open       Date:  2021-11-24       Impact factor: 2.692

10.  A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.

Authors:  Hiroaki Kobayashi; Takeo Kosaka; Kohei Nakamura; Kazunori Shojo; Hiroshi Hongo; Shuji Mikami; Hiroshi Nishihara; Mototsugu Oya
Journal:  BMC Med Genomics       Date:  2021-10-09       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.